Molecule intelOpportunity: Strong0

Glycopyrrolate

8 brands · 3 companies · product forms

1 DRAP alert

Opportunity snapshot

Launch attractiveness
65
Market saturation
8
Price room
100
Regulatory risk
50
8
brands
3
companies
Rs 928.65
median price
3
price points
9.45x
price spread
90
confidence %

Who competes here

Top companies by brand count · leader share 25%

Price room

Across observed sources and strengths
CheapestRs 190
MedianRs 928.65
Most expensiveRs 1,795.5
Spread9.45×
Sources: DVAGO, Servaid

max/min price ratio 9.45x across 3 trusted points (Rs 190.0-1795.5). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory alerts

Recall exposurelatest 2024-10-28
Voluntary Recall Alert: Drug Product; Neo-Pyrolate Injection (Batch # 105B24) Manufactured

Why this score

Launch attractiveness

40% supply-gap(45) + 25% price-variation(100) + 20% low-competition(92) + 15% supply-disruption(40), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

3 canonical companies and 8 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 9.45x across 3 trusted points (Rs 190.0-1795.5). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2024-10-28 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.